Author: Fiona Craig

CyanConnode (LSE:CYAN) reported a strong first-half performance for FY2026, reflecting continued momentum in India’s expanding smart metering market. During the period, the company secured a major £70 million AMISP contract in Goa, a win that almost doubled its order pipeline to £157 million and underlines its growing role in India’s national smart metering rollout.

Revenue for the half year increased 32% year on year to £7.4 million, supported largely by higher hardware shipments. Profitability, however, remained under pressure due to lower margins and rising operating costs. Management said these challenges are being addressed through the introduction of new, lower-cost product offerings aimed at improving margins as volumes scale.

Despite ongoing operational losses, the company’s medium-term outlook remains constructive. CyanConnode expects sustained growth through FY2027, driven by contract execution in India and further expansion into international markets, including the Middle East and North Africa. While recent corporate progress and supportive technical indicators point to potential upside, financial risks remain, particularly around profitability and leverage.

More about CyanConnode Holdings

CyanConnode is a global provider of IoT communications and smart metering solutions focused on energy and infrastructure applications. Its technology portfolio includes narrowband RF mesh, advanced cellular modules, and hybrid communication platforms designed for scalable, cost-effective connectivity. The company’s Omnimesh platform delivers self-forming, self-healing networks, while its Universal Head-End System enables interoperability across multiple technologies. CyanConnode works with utilities and system integrators across regions including India, Southeast Asia, the Middle East, and Europe, supporting the digital transformation of energy networks.

Avacta Group plc (LSE:AVCT) has published new preclinical pharmacology data for its tumour-targeted drug candidate FAP-Exd (AVA6103), highlighting its potential to deliver highly potent cancer therapy directly within tumour tissue. The candidate is designed to release a topoisomerase I inhibitor selectively in the tumour microenvironment, with the aim of improving efficacy while limiting systemic exposure.

The data demonstrated increased tumour-specific cell killing, sustained intratumoural drug release lasting up to five days, and durable anti-tumour responses across preclinical models. Avacta also noted that artificial intelligence has been applied to clinical trial design, helping to optimise patient selection and streamline development. The programme is now being prepared for a Phase 1 clinical trial, targeted to begin in early 2026.

Despite the positive scientific and development milestones, the group continues to face notable financial and valuation pressures. Ongoing losses and dependence on external funding remain key challenges, even as recent technical signals and corporate progress offer some support to the longer-term investment case.

More about Avacta Group plc

Avacta Group plc is a clinical-stage biopharmaceutical company developing novel oncology treatments based on its proprietary pre|CISION® platform. The technology uses tumour-specific protease activation to deliver highly potent drug payloads directly to cancer cells, with the goal of improving therapeutic outcomes while reducing damage to healthy tissue.

ECR Minerals PLC (LSE:ECR) has completed a binding agreement to acquire the Raglan Project, a fully permitted alluvial gold operation located in Queensland, Australia. The transaction, valued at A$1.01 million, will be funded from the company’s existing cash resources.

The acquisition is expected to provide near-term production potential, with mining equipment and supporting infrastructure already in place. Management said Raglan will complement the group’s Blue Mountain operations and support its strategy of accelerating revenue generation while transitioning toward a more production-focused business model.

Beyond immediate operational benefits, the Raglan Project also offers exploration upside and potential tax efficiencies arising from unutilised losses associated with the asset. Together, these factors are expected to contribute to longer-term growth and enhance ECR’s operational footprint in Australia’s gold sector.

More about ECR Minerals

ECR Minerals PLC is an Australia-focused gold exploration and development company. Through its subsidiaries, including ECR Minerals (Australia) Pty Ltd and ECR Minerals (Queensland) Pty Ltd, the group manages a portfolio of projects such as Bailieston, Creswick, Tambo, Blue Mountain, and Lolworth Range, with a strategic emphasis on advancing both production and exploration activities.

Tiger Alpha PLC (LSE:TIR) has provided an update on its wholly owned artificial intelligence infrastructure project, formerly referred to as the Tiger Alpha subnet and now rebranded as the Knowledge Delivery Network (KDN-1). The platform is scheduled for launch in the first quarter of 2026 and is intended to support more efficient, scalable AI operations.

KDN-1 is designed to lower operating costs and reduce latency by caching AI knowledge in a similar way to how content delivery networks distribute digital content. Management believes this approach could significantly improve performance for decentralised AI applications and position the company to benefit from accelerating demand across the decentralised AI ecosystem.

The project is expected to enhance Tiger Alpha’s strategic exposure to emerging AI infrastructure markets, with the potential to attract enterprise users seeking more efficient deployment models. If successful, KDN-1 could strengthen the group’s foothold in frontier technology sectors and support long-term growth opportunities for shareholders.

More about Tiger Alpha PLC

Tiger Alpha PLC is an AIM-listed investment company focused on developing and incubating high-growth opportunities across technology and mining. The group targets frontier areas including artificial intelligence, decentralised infrastructure, and digital asset networks, while continuing to pursue investments in natural resources alongside its technology strategy.

Eden Research plc (LSE:EDEN) has entered into an exclusive distribution agreement with Syngenta Crop Protection AG for its fungicide product Evelta™, covering the professional ornamental crop market across several European Union countries and the UK. The deal represents Eden’s first commercial partnership with a major global crop protection group and marks a significant step in broadening the company’s commercial footprint.

Under the agreement, Syngenta will manage the distribution of Evelta™, supporting Eden’s strategy to accelerate market penetration while maintaining a focus on sustainable crop protection solutions. Management said the partnership is expected to strengthen execution capabilities, extend reach to professional growers, and enhance long-term value creation for stakeholders.

From a market perspective, Eden continues to face financial headwinds alongside cautious technical signals. However, recent corporate developments, including regulatory approvals for its products and instances of insider share purchases, are viewed as constructive indicators that could support future growth and improved investor sentiment.

More about Eden Research

Eden Research plc develops sustainable biopesticide and biocontrol technologies for the global agricultural sector. The company focuses on environmentally responsible fungicides and works with international partners to expand market access, helping growers adopt more sustainable and effective crop protection practices.

Genedrive PLC (LSE:GDR) has launched a “test of change” pilot programme within NHS Grampian and NHS Western Isles to assess the use of its CYP2C19 ID Kit in the treatment of stroke patients across remote and rural communities. The initiative, supported by Scotland’s Centre for Sustainable Delivery, will examine how rapid, point-of-care genetic testing can influence treatment decisions and clinical outcomes in time-critical care settings.

The pilot is intended to demonstrate whether fast pharmacogenetic insights can support more precise prescribing for stroke patients, with positive results potentially enabling broader adoption across Scotland’s NHS network. The programme reinforces Genedrive’s position in the growing field of pharmacogenetic diagnostics and reflects its focus on improving access to advanced healthcare solutions in underserved regions.

From a financial perspective, the company continues to face profitability headwinds despite delivering strong revenue growth and maintaining a robust balance sheet. Market indicators remain cautious, with technical analysis pointing to bearish sentiment and valuation metrics constrained by the absence of sustained profits. Nonetheless, recent operational and clinical milestones are viewed as constructive steps that could strengthen Genedrive’s long-term market positioning.

More about Genedrive

Genedrive PLC is a UK-based diagnostics company specialising in rapid, point-of-care pharmacogenetic testing. Its portfolio includes disposable genetic test kits such as the Genedrive MT-RNR1 ID Kit and the Genedrive CYP2C19 ID Kit, designed to support clinicians in making informed treatment decisions in emergency and time-sensitive environments. The company’s technologies have received recognition within the UK NHS, with a strategic focus on personalised medicine and improved patient outcomes.

First Development Resources Plc (LSE:FDR) has provided an update on ongoing exploration activity at its Selta Project in Australia’s Northern Territory, outlining the next phase of technical work aimed at sharpening gold and rare-earth targets.

The company plans to carry out a high-resolution aeromagnetic and radiometric geophysical survey in early January 2026. The programme is designed to improve structural interpretation across the project area and refine drill targets, with particular focus on the Lander West Gold Target. In parallel, First Development Resources has completed an initial rare-earth element sampling campaign across two areas identified as prospective, with collected samples now submitted for laboratory analysis.

Management said the combined geophysical and geochemical work is intended to systematically progress exploration at Selta, strengthening target definition while maintaining a disciplined, cost-efficient approach to exploration. The results are expected to guide future drilling and field activities as the company continues to assess the project’s mineral potential.

More about First Development Resources Plc

First Development Resources Plc is a UK-based mineral exploration company with projects located in Western Australia and the Northern Territory. The group is focused on exploring for gold and rare-earth elements, targeting geologically favourable regions with the potential to support significant mineral discoveries.

Chesterfield Special Cylinders Holdings plc (LSE:CSC) reported a marked improvement in its financial performance for FY25, with revenue rising 12% year on year to £16.6 million and a return to profitability at the Adjusted EBITDA level, generating £0.8 million. The results reflect a recovery from a difficult FY24 and highlight strengthening momentum across the group’s core operations.

Operational performance was underpinned by record contributions from hydrogen-related activities and Integrity Management services, alongside strong demand from overseas defence customers. The disposal of the PMC division also played a key role in reinforcing the balance sheet, improving financial flexibility and positioning the group for future expansion.

Looking ahead, management expects FY26 to benefit from continued growth opportunities in hydrogen energy infrastructure and global defence programmes. While the broader outlook acknowledges ongoing financial pressures, including historical revenue volatility and net losses, progress in debt reduction and cash flow management represents a step in the right direction. However, technical indicators remain cautious, and the absence of clear valuation benchmarks continues to weigh on investor confidence.

Overall, the group enters the new financial year with improved operational footing, stronger market positioning, and a clearer strategic focus on high-growth, safety-critical sectors.

More about Pressure Technologies

Chesterfield Special Cylinders Holdings plc is a specialist engineering group focused on the design and manufacture of high-pressure gas storage and transportation systems. Its products and services serve safety-critical industries, including defence and hydrogen energy, and are supported by lifecycle offerings such as inspection, testing, and recertification.

U.S. stock index futures are indicating a slightly higher start to Wednesday’s session, pointing to potential gains after markets ended the previous day with mixed results.

Energy shares are expected to be among the early leaders, as crude oil prices have staged a strong recovery from their lowest levels since early 2021. The rebound follows President Donald Trump’s decision to impose a blockade on sanctioned oil tankers operating to and from Venezuela.

In a post on Truth Social, Trump described the government of President Nicolas Maduro as a foreign terrorist organization and announced a “total and complete blockade of all sanctioned oil tankers” entering and leaving Venezuela.

Despite the positive signal from energy markets, overall trading volumes could remain subdued, with investors reluctant to take large positions ahead of Thursday’s release of the highly anticipated U.S. consumer price inflation report.

The November inflation data from the Labor Department is expected to play a key role in shaping expectations for future Federal Reserve interest rate decisions.

Markets struggled for direction on Tuesday, extending the choppy trading pattern seen earlier in the week. Major indexes moved back and forth throughout the session before closing with mixed outcomes.

The Nasdaq Composite rose by 54.05 points, or 0.2%, finishing at 23,111.46. In contrast, the S&P 500 slipped 16.25 points, or 0.2%, to 6,800.26, while the Dow Jones Industrial Average fell 302.30 points, or 0.6%, to 48,114.26.

The uneven performance followed the release of November employment figures from the Labor Department. Although the data showed stronger-than-expected job creation, it came after a sharp decline in employment during October.

Nonfarm payrolls increased by 64,000 in November, reversing part of the 105,000-job drop recorded in October. Economists had anticipated an increase of around 50,000 jobs.

At the same time, the unemployment rate climbed to 4.6% in November from 4.4% in September, exceeding forecasts of 4.5%. This marked the highest unemployment reading since September 2021, when the rate reached 4.7%.

Many economists believe the data strengthens the case for continued interest rate cuts by the Federal Reserve in the near term, while also raising concerns about the broader economic outlook.

“Although the market generally cheers rate cuts, if the Fed is forced to cut rates more aggressively next year because we are headed into a recession, the stock market will drop instead,” said Chris Zaccarelli, Chief Investment Officer for Northlight Asset Management.

Additional economic data from the Commerce Department showed U.S. retail sales were largely flat in October.

Retail sales were essentially unchanged in October after a downwardly revised 0.1% increase in September. Economists had expected a 0.2% gain.

Excluding automobiles, however, retail sales rose by 0.4% in October following a 0.1% increase the previous month, beating expectations for a 0.3% rise.

Sector performance was mixed during Tuesday’s session. Energy stocks suffered sharp losses earlier in the day as crude prices plunged to their lowest levels since early 2021, with the Philadelphia Oil Service Index dropping 4.2% and the NYSE Arca Oil Index falling 3.6%.

Pharmaceutical, healthcare and networking stocks also posted notable declines, while computer hardware shares managed to claw back some recent losses.

European equity markets are showing mixed movements on Wednesday as investors await a series of key central bank policy decisions scheduled for later this week. Announcements are due from the European Central Bank, the Bank of England, Sweden’s Riksbank and Norway’s Norges Bank.

Market sentiment received a boost from fresh data indicating that inflation in the UK cooled more sharply than anticipated in November. According to figures released by the Office for National Statistics, consumer prices rose 3.2% year-on-year, down from 3.6% in October and below the consensus forecast of 3.5%.

Underlying inflation also eased, with the core consumer price index—excluding energy, food, alcohol and tobacco—slowing to 3.2% from 3.4% in the prior month.

Equity performance across the region has diverged. The UK’s FTSE 100 is up around 1.6%, while Germany’s DAX has slipped 0.2% and France’s CAC 40 is down 0.3%.

Sterling weakened against the US dollar following the softer inflation figures, as traders adjusted expectations around future interest rate policy.

At the stock level, shares in Proximus (EU:PROX) moved sharply lower after the digital services and telecommunications group announced that Chief Financial Officer Mark Reid will step down at the end of January 2026 to pursue other opportunities in the UK.

Elsewhere, distribution and services group Bunzl (LSE:BNZL) came under pressure after reaffirming its guidance for adjusted operating profit in 2025.

In contrast, outsourcing specialist Serco Group (LSE:SRP) rallied strongly after issuing profit forecasts for this year and next that exceeded analyst expectations.